Peptide News Digest

Health Canada Finds Bacteria in Seized Peptide Vials, Australian Influencers Selling Peptides, J&J Oral Peptide for Arthritis

Health Canada finds bacteria in seized injectable peptides, ABC tracks influencers selling them in Australia, and J&J's oral peptide meets its arthritis goal.

12 stories · Covering regulatory, industry, clinical-trials, research

Editor's Note

Two of today's stories describe the same supply chain from opposite ends. Health Canada found three bacterial species, two of them Acinetobacter, in injectable products from a Shanghai manufacturer sold through Canadian websites, while ABC News found an Adelaide influencer earning commissions on GHK-Cu from a seller whose lab certificates had been altered; Australia's poisons centre counted 345 cases involving unapproved peptides in the first half of 2026, more than triple its 2025 total. For approved drugs the questions are cost and access: Milwaukee County spent $11 million this year on GLP-1 drugs for its employees and still voted down a copay increase, and New Zealand's regulator has begun reviewing the Wegovy pill. J&J's icotrokinra, an oral peptide that blocks the IL-23 receptor, met its primary goal in psoriatic arthritis, though J&J did not report significance for the stricter ACR50 and ACR70 measures. Most of the remaining research is observational or preclinical, including a records study tying GLP-1 drugs to fewer dementia diagnoses after minor stroke that its authors say needs prospective trials to confirm.

Regulatory

Health Canada Finds Three Bacterial Species in Seized Injectable Products From Shanghai ERP Peptide and Shuts Two Canadian Retail Sites

Health Canada said on November 6 that lab tests of injectable products from Shanghai ERP Peptide Biotechnology found Acinetobacter seifertii, Acinetobacter nosocomialis, and Cutibacterium acnes, and that it had seized more than 11,400 vials from the company and two online retailers, truenorthbiolabs.ca and bcaxiompeptide.com, using court-issued entry warrants. Products named as examples include retatrutide, tirzepatide, tesamorelin, MOTS-c, hCG, and NAD+. Both retail sites are offline, and the agency warns that injecting contaminated products can cause serious infections, hospitalization, and sepsis.

#health-canada #gray-market #retatrutide #tirzepatide
Regulatory

ABC Investigation: Australian Fitness Influencers Earn Commissions Promoting Unapproved Peptides as Poisons Centre Cases Triple

Adelaide influencer Josh Sawyer, 22, told ABC News he earned up to A$2,000 a week in commission while affiliated with Vital Peptides Australia, which sold GHK-Cu and other unapproved peptides; the European testing lab Janoshik confirmed that certificates of analysis displayed by the seller had been altered, and Vital did not respond to the ABC. The Australian Poisons Information Centre recorded 345 poisoning-related cases involving unapproved peptides in the first six months of 2026, more than three times its total for 2025, and the TGA says it has seized and destroyed more than 94,500 unapproved peptide products this year.

#australia #tga #ghk-cu #gray-market
Regulatory

New Zealand's Medsafe Is Reviewing Its First Application for a GLP-1 Weight-Loss Pill, Wegovy Tablets

Medsafe has received an application for Wegovy oral tablets under one of its reliance pathways, which draw on decisions by trusted overseas regulators to halve target review times, and aims to finish the initial assessment in about 75 working days, 1News reported on November 7. No other weight-loss drug is under consideration, and the Royal New Zealand College of General Practitioners' medical director, Dr. Prabani Wood, said no decision has been made on funding and access.

#wegovy-pill #oral-semaglutide #novo-nordisk
Industry

Milwaukee County Spent $11 Million on Employees' GLP-1 Drugs This Year, Then Voted Down a Copay Increase

After an hourslong debate on Thursday, November 5, the Milwaukee County Board of Supervisors rejected Supervisor Shawn Rolland's amendment to raise employee copays for GLP-1 drugs from $40 to $150 and, as WISN described it, offer them only to people with diabetes. Supervisor Sheldon Wasserman, a physician who supports the drugs' use, expects the county's cost to rise to as much as $15 million next year; Supervisor Deanna Alexander said the higher copay would have added $1,320 a year for patients following their doctors' plans.

#glp-1 #obesity-coverage
Clinical Trials

J&J's Oral Peptide Icotyde Met Its Main Goal in Psoriatic Arthritis, With 58% Reaching ACR20 at Week 16 vs. 41% on Placebo

In the Phase 3 ICONIC-PsA 1 trial (NCT06878404) in adults with active psoriatic arthritis who had not taken a biologic, 58% on once-daily icotrokinra 200 mg reached ACR20 at week 16 vs. 41% on placebo; ACR50 rates were 29% vs. 16% and ACR70 rates 13% vs. 5%, and J&J did not state significance for either. Among patients with enough psoriasis to score, 57% vs. 14% had clear or almost clear skin (nominal p<0.001). J&J announced the late-breaking ACR Convergence 2026 data on November 7; Icotyde, which blocks the IL-23 receptor, is approved in the U.S. for plaque psoriasis but not psoriatic arthritis.

#icotrokinra #oral-peptides #psoriasis #psoriatic-arthritis
Research

Novo Real-World Data at AASLD: Wegovy Users With MASH Had Larger Drops in AST and Weight Than Resmetirom Users Over Six Months

In PLATINUM-Truveta, a retrospective analysis of health records from 30 U.S. health systems, AST fell 10.4 U/L at six months in 2,873 adults with MASH on semaglutide 2.4 mg vs. 4.5 U/L in 2,285 on resmetirom, and weight fell 18.9 lb vs. 5.6 lb; the ALT difference was not significant, and LDL cholesterol fell more on resmetirom. Novo, which presented the data at The Liver Meeting in Denver on November 6, says the groups differed at baseline and the observational design cannot establish causation.

#semaglutide #mash #resmetirom #real-world-evidence
Industry

Indian Contract Manufacturer Shilpa Commits $50 Million to a Peptide Plant in Karnataka, With the Commercial Line Due in December

Shilpa said at the TIDES Europe conference in Amsterdam that it is spending $50 million to expand commercial peptide manufacturing on its export-oriented, 34-acre campus in Raichur, Karnataka, with reactors of up to 1,000 liters and capacity of up to one metric ton a year, BioProcess International reported on November 6. CEO Keshav Bhutada said the commercial line is on track to open in December 2026; the company plans to make GLP-1 peptides, longer peptides for cancer and rare diseases, and more cytotoxic and peptide-conjugate payloads.

#peptide-manufacturing #cdmo #india
Research

Dalhousie-Led Panel of 45 Recommends Screening for Eating Disorders Before Starting a GLP-1 Drug

In a three-round Delphi process published in World Psychiatry, 45 panelists, including specialists in diabetes, obesity, and eating disorders and people with lived experience, agreed that clinicians should screen for current and past eating disorders with a brief validated questionnaire before prescribing GLP-1 drugs and monitor symptoms during treatment. The panel says the drugs should generally be avoided in people with active anorexia nervosa, atypical anorexia nervosa, or bulimia with marked dietary restraint, and notes that evidence on GLP-1 drugs and eating disorders remains limited and inconsistent.

#glp-1 #mental-health #eating-disorders
Research

GLP-1 Drug Users Had About Half the Rate of Dementia Diagnoses After a Minor Stroke in a TriNetX Records Study

Researchers led from West Virginia University matched 1,425 adults with minor ischemic stroke who took a GLP-1 drug before or within three months of the stroke with 1,425 who did not; 92.7% had diabetes. Over five years, 3.4% vs. 7.0% were diagnosed with dementia (hazard ratio 0.52, 95% CI 0.37 to 0.74), and 4.4% vs. 8.8% died. The Journal of Neurology authors say prospective trials are needed to confirm causality.

#glp-1 #stroke #dementia #real-world-evidence
Clinical Trials

Belgian Pilot: Four Weeks of Nasal Oxytocin Changed White-Matter Tracts in Autistic Men, and Some Changes Tracked Social Gains

The placebo-controlled pilot in 27 young adult men with autism, published in Translational Psychiatry by Hasselt University and KU Leuven researchers, tested 24 IU of intranasal oxytocin daily for four weeks, with brain diffusion imaging at baseline, after treatment, and four weeks and one year later. Oxytocin was linked to higher fractional anisotropy in the uncinate fasciculus on both sides and mixed changes in two other tracts, mostly increases on the right and decreases on the left; changes in some tracts correlated with better social responsiveness and less avoidant attachment. The authors call the findings exploratory and hypothesis-generating.

#autism #neurology #intranasal-oxytocin
Research

Rzeszów Team's Cobra-Venom-Inspired Peptide AMPAB5 Breaks Up Pseudomonas Biofilms and Boosts Chloramphenicol 16-Fold in Lab Tests

Researchers at Rzeszów University of Technology, with colleagues in Gdańsk, Kraków, and Ljubljana, built AMPAB5 from cobra (Naja ashei) venom factor sequences. Against Pseudomonas aeruginosa, which resists chloramphenicol (MIC 250 μg/mL), combining the two cut the MICs to 15.63 μg/mL for the antibiotic and 5.86 μg/mL for the peptide; AMPAB5 also blocked and cleared biofilms, modulated IL-1β and TNF-α release by human macrophages, and showed no hemolysis or toxicity to skin or Caco-2 cells, the Toxicology and Applied Pharmacology paper reports. The work was done in cells only, and two authors hold a patent assigned to the university.

#antimicrobial-peptides #venom-peptides #antibiotic-resistance
Research

Nanjing Mouse Study: The Mitochondrial Peptide Humanin Limits Kidney Scarring After Acute Injury

Researchers at Nanjing Medical University and Southeast University found that kidney humanin levels fell after ischemia-reperfusion injury in mice and tracked with declining kidney function and fibrosis. The analog S14G-humanin protected against fibrosis by stabilizing Suclg1, a subunit of a mitochondrial enzyme, against TRIM28-driven breakdown, and blocking Suclg1 erased the benefit, the Free Radical Biology and Medicine paper reports. The work was done in mice and has not been tested in people.

#humanin #kidney-disease #preclinical

Related Guides